Ascendis Pharma A/S (NASDAQ:ASND) Given New $254.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus has raised the price target for Ascendis Pharma A/S (NASDAQ:ASND) from $212.00 to $254.00, indicating a potential upside of 41.78% from the stock's previous close.
• Other analysts, including JPMorgan and Citigroup, have also increased their price targets, with an average target of $226.80 and a consensus rating of "Moderate Buy."
• Ascendis Pharma reported an earnings per share (EPS) of ($0.93), exceeding analyst expectations and generating revenue of $216.28 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target raised by analysts at Stifel Nicolaus from $212.00 to $254.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. Stifel Nicolaus' price objective suggests a potential upside of 30.64% from the stock's previous close.

Several other brokerages also recently issued reports on ASND. Morgan Stanley assumed coverage on Ascendis Pharma A/S in a research report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. Oppenheimer restated an "outperform" rating and issued a $224.00 target price (up from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Bank of America upped their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Wells Fargo & Company restated an "overweight" rating and issued a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday. Finally, Evercore ISI upped their target price on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Seventeen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $239.80.

Ascendis Pharma A/S Trading Down 0.8%

Ascendis Pharma A/S stock traded down $1.55 during midday trading on Friday, hitting $194.42. The stock had a trading volume of 541,885 shares, compared to its average volume of 494,629. The stock has a market cap of $11.89 billion, a P/E ratio of -37.77 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $199.99. The business has a fifty day moving average price of $174.44 and a 200 day moving average price of $159.76.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. On average, equities analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Large investors have recently bought and sold shares of the business. RA Capital Management L.P. boosted its holdings in Ascendis Pharma A/S by 1.7% during the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company's stock valued at $1,602,474,000 after acquiring an additional 168,752 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 2.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after buying an additional 114,167 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of Ascendis Pharma A/S by 12.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after buying an additional 328,278 shares during the period. Finally, Capital International Investors lifted its stake in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after buying an additional 753,859 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.